Solosec (Secnidazole) Patent Expiration, LOE Window & CMS Spending

Solosec (Secnidazole) by Evofem: FDA Orange Book LOE 2041-12-11, 0 AB generics, $671K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEvofem
FDA Application & PathwayN209363 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-12-11
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$671K
2024 Medicare Part D Spend$56K
2024 Medicaid Spend$615K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel